Attana (ATANA) Q1 2026 earnings summary

Executive summary

• Focused on biosensor development, consumables, and CRO services for biotech and pharma sectors.

• Strategic shift towards commercial scalability and recurring revenues, especially in the CRO segment.

• Entered a pilot project with Offspring Biosciences to validate biosensor technology in early drug development.

• USPTO approved a key piezoelectric sensor technology patent, enhancing IP portfolio.

• Technology featured in a Nature Communications article, boosting scientific credibility.

Financial highlights

• Net sales for Q1 2026: 0.43 MSEK, down from 1.59 MSEK year-over-year.

• Operating loss: -1.71 MSEK (Q1 2025: -0.43 MSEK).

• Net loss after tax: -1.71 MSEK (Q1 2025: -0.43 MSEK).

• Earnings per share: -0.0007 (Q1 2025: -0.0003).

• Cash and cash equivalents at period end: 0.11 MSEK (Q1 2025: -0.14 MSEK).

Outlook and guidance

• Ongoing evaluation of capital raise to secure operations and support commercial development.

• Continued focus on CRO market, recurring revenues, and strategic partnerships.

• Market for biologically relevant analysis methods is expanding, with technology well positioned.